705 related articles for article (PubMed ID: 17688284)
1. Role of nanotechnology in pharmaceutical product development.
Devalapally H; Chakilam A; Amiji MM
J Pharm Sci; 2007 Oct; 96(10):2547-65. PubMed ID: 17688284
[TBL] [Abstract][Full Text] [Related]
2. Nanocarriers.
Torchilin VP
Pharm Res; 2007 Dec; 24(12):2333-4. PubMed ID: 17934800
[TBL] [Abstract][Full Text] [Related]
3. Pharmaceutical development and regulatory considerations for nanoparticles and nanoparticulate drug delivery systems.
Narang AS; Chang RK; Hussain MA
J Pharm Sci; 2013 Nov; 102(11):3867-82. PubMed ID: 24037829
[TBL] [Abstract][Full Text] [Related]
4. In silico predictions of gastrointestinal drug absorption in pharmaceutical product development: application of the mechanistic absorption model GI-Sim.
Sjögren E; Westergren J; Grant I; Hanisch G; Lindfors L; Lennernäs H; Abrahamsson B; Tannergren C
Eur J Pharm Sci; 2013 Jul; 49(4):679-98. PubMed ID: 23727464
[TBL] [Abstract][Full Text] [Related]
5. Nanoparticulate strategies for effective delivery of poorly soluble therapeutics.
Gokce EH; Ozyazici M; Souto EB
Ther Deliv; 2010 Jul; 1(1):149-67. PubMed ID: 22816125
[TBL] [Abstract][Full Text] [Related]
6. PBPK models for the prediction of in vivo performance of oral dosage forms.
Kostewicz ES; Aarons L; Bergstrand M; Bolger MB; Galetin A; Hatley O; Jamei M; Lloyd R; Pepin X; Rostami-Hodjegan A; Sjögren E; Tannergren C; Turner DB; Wagner C; Weitschies W; Dressman J
Eur J Pharm Sci; 2014 Jun; 57():300-21. PubMed ID: 24060672
[TBL] [Abstract][Full Text] [Related]
7. Oral biopharmaceutics tools - time for a new initiative - an introduction to the IMI project OrBiTo.
Lennernäs H; Aarons L; Augustijns P; Beato S; Bolger M; Box K; Brewster M; Butler J; Dressman J; Holm R; Julia Frank K; Kendall R; Langguth P; Sydor J; Lindahl A; McAllister M; Muenster U; Müllertz A; Ojala K; Pepin X; Reppas C; Rostami-Hodjegan A; Verwei M; Weitschies W; Wilson C; Karlsson C; Abrahamsson B
Eur J Pharm Sci; 2014 Jun; 57():292-9. PubMed ID: 24189462
[TBL] [Abstract][Full Text] [Related]
8. Rationalizing the selection of oral lipid based drug delivery systems by an in vitro dynamic lipolysis model for improved oral bioavailability of poorly water soluble drugs.
Dahan A; Hoffman A
J Control Release; 2008 Jul; 129(1):1-10. PubMed ID: 18499294
[TBL] [Abstract][Full Text] [Related]
9. Location, location, location: gastrointestinal delivery site and its impact on absorption.
Connor A
Ther Deliv; 2012 May; 3(5):575-8. PubMed ID: 22834401
[No Abstract] [Full Text] [Related]
10. Biopharmaceutical challenges associated with drugs with low aqueous solubility--the potential impact of lipid-based formulations.
O'Driscoll CM; Griffin BT
Adv Drug Deliv Rev; 2008 Mar; 60(6):617-24. PubMed ID: 18155800
[TBL] [Abstract][Full Text] [Related]
11. Availability of polymeric nanoparticles for specific enhanced and targeted drug delivery.
Kiriyama A; Iga K; Shibata N
Ther Deliv; 2013 Oct; 4(10):1261-78. PubMed ID: 24116911
[TBL] [Abstract][Full Text] [Related]
12. Delivery and targeting of nanoparticles into hair follicles.
Fang CL; Aljuffali IA; Li YC; Fang JY
Ther Deliv; 2014; 5(9):991-1006. PubMed ID: 25375342
[TBL] [Abstract][Full Text] [Related]
13. Nanocarriers protecting toward an intestinal pre-uptake metabolism.
Suchaoin W; Bernkop-Schnürch A
Nanomedicine (Lond); 2017 Feb; 12(3):255-269. PubMed ID: 28093952
[TBL] [Abstract][Full Text] [Related]
14. Early pharmaceutical profiling to predict oral drug absorption: current status and unmet needs.
Bergström CA; Holm R; Jørgensen SA; Andersson SB; Artursson P; Beato S; Borde A; Box K; Brewster M; Dressman J; Feng KI; Halbert G; Kostewicz E; McAllister M; Muenster U; Thinnes J; Taylor R; Mullertz A
Eur J Pharm Sci; 2014 Jun; 57():173-99. PubMed ID: 24215735
[TBL] [Abstract][Full Text] [Related]
15. Formulation design for poorly water-soluble drugs based on biopharmaceutics classification system: basic approaches and practical applications.
Kawabata Y; Wada K; Nakatani M; Yamada S; Onoue S
Int J Pharm; 2011 Nov; 420(1):1-10. PubMed ID: 21884771
[TBL] [Abstract][Full Text] [Related]
16. Nanoengineered drug delivery systems for enhancing antibiotic therapy.
Kalhapure RS; Suleman N; Mocktar C; Seedat N; Govender T
J Pharm Sci; 2015 Mar; 104(3):872-905. PubMed ID: 25546108
[TBL] [Abstract][Full Text] [Related]
17. A review of the formation and classification of amphiphilic block copolymer nanoparticulate structures: micelles, nanospheres, nanocapsules and polymersomes.
Letchford K; Burt H
Eur J Pharm Biopharm; 2007 Mar; 65(3):259-69. PubMed ID: 17196803
[TBL] [Abstract][Full Text] [Related]
18. BCS class IV drugs: Highly notorious candidates for formulation development.
Ghadi R; Dand N
J Control Release; 2017 Feb; 248():71-95. PubMed ID: 28088572
[TBL] [Abstract][Full Text] [Related]
19. Pharmaceutical product development technologies based on the biopharmaceutical classification system.
Jain D; Pathak D; Pathak K
Pharmazie; 2009 Aug; 64(8):483-90. PubMed ID: 19746834
[TBL] [Abstract][Full Text] [Related]
20. Engineered nanoparticulate drug delivery systems: the next frontier for oral administration?
Diab R; Jaafar-Maalej C; Fessi H; Maincent P
AAPS J; 2012 Dec; 14(4):688-702. PubMed ID: 22767270
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
